Alterity Therapeutics

Alterity Therapeutics company information, Employees & Contact Information

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. Our goal is to modify the course of these diseases and improve quality of life. Our lead asset, ATH434, has the potential to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. Alterity has offices in Melbourne, Australia and San Francisco, USA.

Company Details

Employees
12
Address
Melbourne, Vic 3000, Au
Phone
+61 3 9824 8166
Email
in****@****bio.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Melbourne, VIC
Looking for a particular Alterity Therapeutics employee's phone or email?

Alterity Therapeutics Questions

News

Alterity Therapeutics to Present at the Biotech Showcase - GlobeNewswire

Alterity Therapeutics to Present at the Biotech Showcase GlobeNewswire

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - Yahoo Finance

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy Yahoo Finance

First Potential Treatment for MSA: Alterity's ATH434 Phase 2 Results Show Disease Progression Slowdown - Stock Titan

First Potential Treatment for MSA: Alterity's ATH434 Phase 2 Results Show Disease Progression Slowdown Stock Titan

Alterity Therapeutics to Deliver Multiple Presentations at - GlobeNewswire

Alterity Therapeutics to Deliver Multiple Presentations at GlobeNewswire

Alterity Therapeutics Raises A$20.0 million in Strategic Placement - The Manila Times

Alterity Therapeutics Raises A$20.0 million in Strategic Placement The Manila Times

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study - Yahoo Finance

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study Yahoo Finance

Neurodegenerative Disease Biotech Alterity Therapeutics Sets Corporate Update at Global Showcase - Stock Titan

Neurodegenerative Disease Biotech Alterity Therapeutics Sets Corporate Update at Global Showcase Stock Titan

Alterity Therapeutics Presents Positive Data from ATH434 - GlobeNewswire

Alterity Therapeutics Presents Positive Data from ATH434 GlobeNewswire

Neurodegenerative Drug Developer Alterity Raises A$20M After Promising Multiple System Atrophy Results - Stock Titan

Neurodegenerative Drug Developer Alterity Raises A$20M After Promising Multiple System Atrophy Results Stock Titan

ATH434 Continues to Demonstrate Positive Efficacy in Latest Phase 2 Data Readout - NeurologyLive

ATH434 Continues to Demonstrate Positive Efficacy in Latest Phase 2 Data Readout NeurologyLive

Alterity Therapeutics Raises A$20.0 million in Strategic Placement - GlobeNewswire

Alterity Therapeutics Raises A$20.0 million in Strategic Placement GlobeNewswire

Disease-Modifying Success: Alterity's ATH434 Drug Shows Meaningful Efficacy in Rare Brain Disease Trial - Stock Titan

Disease-Modifying Success: Alterity's ATH434 Drug Shows Meaningful Efficacy in Rare Brain Disease Trial Stock Titan

Alterity Therapeutics Raises A$40.0 million in Placement - GlobeNewswire

Alterity Therapeutics Raises A$40.0 million in Placement GlobeNewswire

Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability - Yahoo Finance

Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability Yahoo Finance

Breakthrough: FDA Fast-Tracks Novel MSA Drug ATH434 - First Potential Treatment for Fatal Brain Disease - Stock Titan

Breakthrough: FDA Fast-Tracks Novel MSA Drug ATH434 - First Potential Treatment for Fatal Brain Disease Stock Titan

Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Yahoo Finance

Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 Yahoo Finance

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy - GlobeNewswire

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy GlobeNewswire

Alterity Therapeutics Announces Positive ATH434 Phase 2 - GlobeNewswire

Alterity Therapeutics Announces Positive ATH434 Phase 2 GlobeNewswire

We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth - Yahoo Finance

We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth Yahoo Finance

Alterity Therapeutics Reports 48% Treatment Effect for ATH434 in Phase 2 MSA | ATHE Stock News - Stock Titan

Alterity Therapeutics Reports 48% Treatment Effect for ATH434 in Phase 2 MSA | ATHE Stock News Stock Titan

Positive Interim Phase 2 Data Reported for Multiple System Atrophy Agent ATH434 - NeurologyLive

Positive Interim Phase 2 Data Reported for Multiple System Atrophy Agent ATH434 NeurologyLive

Orphan Disease Biomarkers Market Size, Report by 2034 - Precedence Research

Orphan Disease Biomarkers Market Size, Report by 2034 Precedence Research

Multiple System Atrophy Agent ATH434 Shows Promising Topline Efficacy in Phase 2 Trial - NeurologyLive

Multiple System Atrophy Agent ATH434 Shows Promising Topline Efficacy in Phase 2 Trial NeurologyLive

Breakthrough MSA Treatment Achieves 48% Disease Slowdown in Phase 2 Trial - Stock Titan

Breakthrough MSA Treatment Achieves 48% Disease Slowdown in Phase 2 Trial Stock Titan

Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - NeurologyLive

Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 NeurologyLive

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) PR Newswire

Health Kick Podcast: Alterity Therapeutics - The Australian

Health Kick Podcast: Alterity Therapeutics The Australian

Alterity Therapeutics Confirms Effectiveness of ATH434 Drug Against Advanced MSA - smallcaps.com.au

Alterity Therapeutics Confirms Effectiveness of ATH434 Drug Against Advanced MSA smallcaps.com.au

Alterity Therapeutics (ASX:ATH) more than doubled after its Phase 2 results, but its still only $80m - Stocks Down Under

Alterity Therapeutics (ASX:ATH) more than doubled after its Phase 2 results, but its still only $80m Stocks Down Under

StockTake: Alterity Therapeutics - The Australian

StockTake: Alterity Therapeutics The Australian

ATH Stock Price and Chart — ASX:ATH - TradingView

ATH Stock Price and Chart — ASX:ATH TradingView

Top Alterity Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant